Clinical Trials Logo

H3 K27M clinical trials

View clinical trials related to H3 K27M.

Filter by:
  • None
  • Page 1

NCT ID: NCT05956821 Recruiting - Clinical trials for Glioblastoma Multiforme

Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

Start date: August 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study assesses the safety and efficacy of repeat monthly dosing of super-selective intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab in patients < 22 years of age.

NCT ID: NCT05580562 Recruiting - Glioma Clinical Trials

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

ACTION
Start date: January 23, 2023
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC201 following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.

NCT ID: NCT04617002 Available - Glioma Clinical Trials

Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

Start date: n/a
Phase:
Study type: Expanded Access

This is an intermediate-size expanded access protocol to provide ONC201 (dordaviprone) to patients with H3 K27M-mutant and/or midline gliomas who cannot access ONC201 (dordaviprone) through clinical trials.